Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

d Generation Rhu FSH in Non-Regulated Markets

• 3rd Generation Rhu FSH

• Purified Urinary Human Choriogonadotropin (hCG)

• Recombinant Human Choriogonadotropin (rhCG)

• Recombinant Human Luteinizing Hormone (rhLH)

• hCG Receptor Agonist

 

9 ) Thrombolytics & Fibrinolytics

 

• Non-fibrin selective (1st generation) Fibrinolytics

• Fibrin selective wild-type t-PA-based Fibrinolytics

• Fibrin selective engineered t-PA-based Fibrinolytics

• Non-t-PA-based Fibrinolytics

• Plasmin-based Fibrinolytics

• Adjunctive therapy to Fibrinolytics

• Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets

• Corporate Thrombolytic Product Portfolios and R&D Pipelines

 

10) Enzyme Replacement Therapies

 

• Gaucher Disease

• Fabry Disease

• Pompé Disease

• Hunter Disease (MPS II)

• Niemann Pick Diseases

• Mucopolysaccharidosis I (MPS I)

• San Filippo Syndrome (MPS IIIA)

• Morquio Syndrome (MPS IVA)

• Mucopolysaccharidosis VI (MPS VI)

• Tay-Sachs Disease

• Chronic Deficiency of Adenosine Deaminase

• Phenylketonuria / Hyperphenylalaninemia

• Other Enzyme Replacement Therapies

• Exocrine Pancreatic Insufficiency: Porcine-Derived ERT

• Exocrine Pancreatic Insufficiency: Recombinant ERT

• Others

 

 

 

To order this report:

Biopharmaceutical Industry:

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire/ ... today announced that David R. Parkinson , ... (NEA), has been appointed to the board of ... twenty years of experience in oncology clinical development, ... that resulted in global approvals of the cancer ...
(Date:5/5/2015)... Synedgen Inc. is pleased to announce ... Manager. , Dr. Nguyen brings to Synedgen critical regulatory ... company as it moves forward in the FDA regulatory ... two years. Dr. Nguyen will lead the management of ... documents that must be completed in order to initiate ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - JSS Medical Research Inc., a ... today that it concluded the acquisition of Max Neeman International (MNI), ... Additional regional offices are located in Ahmedabad, Bangalore ... . Through a US subsidiary, a regional office is located ... expansion is supported by the recent equity investment transaction into JSS ...
(Date:5/4/2015)... BROOK, N.Y. , May 4, 2015 /PRNewswire/ ... a $250,000 cooperative research and development agreement (CRADA) ... to advance the development of TRB-N0224 for the ... animals, including dogs and cats.  Traverse Biosciences has ... TRB-N0224 for the treatment and control of periodontal ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4
... - In a letter to the co-chairs of the state's ... Kanavas has called for a performance review audit on ... , ,In the letter, addressed to Senator Jim Sullivan ... Falls, Kanavas referenced several security breaches, including the printing of ...
... venture capital arm of Boston's Peak Ridge Capital Group, ... raising capital and is ready to scout for early-stage investments ... to be capped at $50 million, has not raised that ... according to Michael McNally, chairman and CEO of Peak Ridge. ...
... visit to the Menomonee Valley, Gov. Jim Doyle ... state budget for the new Wisconsin Venture Center. , ,Doyle ... that will connect entrepreneurs with sources of capital, and serve ... in Wisconsin. , ,The concept was announced in December of ...
Cached Biology Technology:Avolte Venture Partners reaches capital goal 2Doyle proposes $2M for venture capital center 2
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... known to activate store-operated calcium channels has been found ... at Temple University. The researchers published their findings, ... Cav1.2 Channels, in the Oct. 1 issue of ... just important for bones and teeth, is a universal ...
... the perfect partner differs greatly from our real-life partner, according ... University of Montpellier in France. The research found that our ... mass index than those we would ideally choose. ... in the Journal PLoS ONE , found that most ...
... Institute of Technology has been awarded a $13.1 ... and Technology to assist in construction of a ... Golisano Institute for Sustainability. The building will serve ... education and outreach and provide a state-of-the-art showcase ...
Cached Biology News:Protein provides link between calcium signaling in excitable and non-excitable cells 2Study shows real partners are no match for ideal mate 2RIT receives federal grant to construct new sustainability research facility 2RIT receives federal grant to construct new sustainability research facility 3RIT receives federal grant to construct new sustainability research facility 4
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
IkappaB-alpha (112B2) Mouse mAb...
Biology Products: